Russia's Nativa plans to start production of Novartis anticancer drug

31 October 2018

Russian drugmaker Nativa, which is known for its legal battles with global pharmaceutical companies over intellectual property issues, is applying to receive a compulsory license for the production of a generic version of anticancer drug nilotinib (trade name Tasigna), reports The Pharma Letter’s local correspondent.

Tasigna is protected by a patent held by Swiss pharma giant Novartis (NOVN: VX) until the middle of 2023, according to the Russian company.

To date, Nativa has already appealed to the Moscow Arbitration Court with a claim against Novartis and the Russian Federal Agency for Intellectual Property, Patents and Trademarks (Rospatent).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK